PR
News
notice
Xcell Therapeutics Promotes with German Company PELO BIOTHECH..."Actively Addressing the Exosome Market"
2022.05.30
Xcell Therapeutics Promotes with German Company PELO BIOTHECH..."Actively Addressing the Exosome Market"
Xcell Therapeutics, a leading domestic media company, announced today that it has conducted a joint promotion with Germany's PELO Biotech at the recent International Society of Exosomes (ISEV 2022) in Lyon, France.
A "medium" is a mixture that is designed to grow microorganisms or cells. Different media are used for different types of cultures.
According to Xcell Therapeutics, the company participated in ISEV, which was held from May 25-29, and displayed experimental data on exosome-specific media as a poster, and conducted a joint promotion with employees of Germany-based PELO Biotech.
Xcell Therapeutics also plans to develop exosome-specific stem cell media (serum-free chemotactic media) to respond to the rapidly growing exosome market at home and abroad by utilizing its own media development platform (CAMPs).
An official from Xcell Therapeutics said, "The advantage of our medium development platform (CAMPs) is that we can develop the optimal medium recipe in the shortest period of time." "If the development proceeds as planned, we will be able to launch the exosome-specific medium in the fourth quarter."
Exosomes are extracellular vesicles (EVs) that cells release into the environment. Exosomes are small, 20-100 nanometer (nm) vesicles. They play an important role in cell-to-cell signal transduction and are being considered as a next-generation drug delivery system. In addition, since they are bio-derived, they have fewer side effects, so the competition to develop therapeutics using exosomes is active.
Xcell Therapeutics is the first company in the world to develop a chemically composed serum-free medium for stem cells graded as cGMP, and directly owns and operates a GMP-grade production plant capable of producing 100,000 liters per year in Yongin.
Dr. Lee, CEO of Xcell Therapeutics, said, "Securing high purity exosomes and ensuring yield through mass culture are the biggest barriers faced by exosome companies. We are confident that the exosome-specific media that Xcell Therapeutics will provide will be a good solution to solve both issues at once."